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Abstract
It has been estimated that up to 50% of patients with type 1 or type 2 diabetes 
will have the complication of neuropathy. The impact of autonomic neu-
ropathy in diabetes is often underestimated, but it can result in a range of 
debilitating symptoms including orthostatic hypotension, gastroparesis, 
disordered gastrointestinal motility, impotence and bladder dysfunction, 
and it also carries an increased risk of cardiovascular mortality. Reduced 
blood supply, impaired nerve regeneration, deficient axonal transport, 
loss of neurotrophic support and metabolic changes induced by hyper-
glycemia including mitochondrial dysfunction have all been implicated 
in the development of diabetic neuropathy. Many of these deficits can 
lead to the production of oxidative stress that appears to be a common 
factor leading to nerve damage. Studies of animal models have revealed 
that not all subpopulations of autonomic nerves degenerate in diabetes 
and that some populations are more difficult to treat once neuropathy 
has developed. Recent evidence indicates that differences in the level of 
metabolic activity and in the intrinsic defence mechanisms of subpopu-
lations of autonomic neurons may account for their differential suscep-
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1. Introduction
The incidence of diabetes mellitus has been described 
as reaching epidemic proportions, particularly in the 
Western world. It has been estimated that up to 50% 
of patients with type 1 or type 2 diabetes will have the 
complication of neuropathy [1]. When the autonomic 
nervous system is affected, this can lead to a variety 
of symptoms such as tachycardia, orthostatic hypo-
tension, gastroparesis, constipation, diarrhea, fecal 
incontinence, impotence and bladder dysfunction, 
thus significantly affecting the quality of life of diabetic 
patients. Furthermore, the presence of autonomic neu-
ropathy carries a significant increased risk of cardio-
vascular mortality. Deficits in the autonomic supply 
to the skin can also disrupt microvascular flow and 
impair sweating, contributing to the development of 
foot ulcers that occur as a consequence of the sen-
sory deficits associated with sensory neuropathy in 
diabetes [2,3]. Chronic foot ulcers that fail to heal are 
a major cause of nontraumatic amputation. There is 
thus a substantial clinical need to understand the 
mechanisms underlying autonomic neuropathy in 
diabetes and to find potential treatments that can 
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prevent its development and treat the condition once 
it has occurred. Despite this, it has been observed 
that autonomic neuropathy is the least recognized 
and least understood complication of diabetes [3].
2. Clinical assessment
Historically, the assessment of peripheral neuropathy 
in diabetes has focused on myelinated nerves, largely 
due to technical reasons. In morphometric studies 
of human sural nerve biopsies, the standard tissue 
for microscopy analysis, it has proved easier to quan-
tify changes in myelinated axons than unmyelinated 
axons. Similarly, the standard functional test of nerve 
conduction velocity provides no information on con-
duction in unmyelinated nerves [1,4,5]. With the intro-
duction of new immunohistochemical markers and 
microscopy techniques, the use of skin biopsies in the 
detection of diabetic neuropathy has recently been 
developed. A loss of small unmyelinated sensory fibers 
has been demonstrated in the skin from diabetic pa-
tients. Significantly, a loss of small sensory fibers 
has been observed in diabetic patients with normal 
conduction velocity measurements [1,5]. This coincides 
with the view that changes in unmyelinated nerve 
fibers (both small sensory and autonomic) occur at 
an early stage in diabetes [4]. Whether a clinical entity 
separate from peripheral neuropathy exists in diabetes 
in which there is selective loss of small fibers with rel-
ative preservation of large sensory fibers, termed “small 
fiber neuropathy” is still a matter of debate [6,7].
One of the problems with evaluating the particular 
significance of autonomic neuropathy in diabetes is 
that pathological changes in autonomic nerves can be 
present before the development of overt symptoms. 
Furthermore, autonomic function is difficult to assess 
clinically using noninvasive techniques. At present, the 
only standard approach used to evaluate autonomic 
function in humans with diabetes relies on the mea-
surement of heart rate and blood pressure responses 
to deep breathing, standing and the Valsalva maneuver. 
Loss of heart rate variability is the earliest indicator 
of cardiovascular autonomic neuropathy, and 7–10% 
of newly diagnosed type 1 diabetes patients have 
been reported to have abnormal heart rate variability. 
Thus, there is evidence, at least for within the cardio-
vascular system, that autonomic neuropathy is an early 
complication of diabetes [see reference 8 for review]. 
Furthermore, the 5-year mortality rate in diabetic pa-
tients with evidence of cardiovascular autonomic neu-
ropathy is significantly higher than in diabetic patients 
without such signs [3,8,9]. Research is ongoing into 
the development of alternative tests of autonomic 
function including assessment of pupillary, sudomo-
tor, bladder and erectile function [see reference 3 for 
review]. However, these have yet to become routine 
clinical practice. Furthermore, the majority of such 
tests assess reflex activity and do not provide infor-
mation on the specific sites within peripheral auto-
nomic pathways that are most susceptible to damage. 
The presence of pathological changes in the autonomic 
supply of visceral organs in diabetes in humans is often 
inferred from indirect evidence such as the presence 
of abnormal cardiovascular function tests and/or overt 
symptoms. Therefore, elucidation of the nature of the 
pathological changes that occur in autonomic nerves 
in diabetes has largely relied on studies of animal 
models.
3. Autonomic neuropathy in 
experimental diabetes
There are two main categories of animal models of 
diabetes: (1) those in which type 1 diabetes is induced 
by a chemical toxin that destroys the insulin-secreting 
pancreatic islet cells; and (2) those in which strains of 
mice or rats that are genetically predisposed to devel-
oping either type 1 or type 2 diabetes are selectively 
bred. The most commonly used chemical model is the 
streptozotocin (STZ)-diabetic rat. More recently, two 
spontaneously diabetic rat strains (BB/Wor and BBZDR/
Wor), closely related genetically, are receiving consid-
erable attention. These strains enable the comparison 
of neuropathic changes in type 1 and type 2 diabetes 
since the BB/Wor rat is a hyperglycemic, hypoinsuline-
mic model of type 1 diabetes and the BBZDR/Wor rat 
is a hyperglycemic, hyperinsulinemic model of type 2 
diabetes [10]. A detailed description of all the changes 
that have been observed in the autonomic nervous 
system in experimental diabetes is beyond the scope 
of this brief review [see reference 11 for a compre-
hensive overview]. Therefore, only characteristic or 
significant features will be highlighted here.
Where comparable tissues have been available for 
study, the results are encouraging that changes that 
occur experimentally in animals also occur in diabetes 
in humans. For example, impaired parasympathetic 
control of erectile tissue mediated by nitric oxide 
has been implicated in erectile dysfunction in both 
clinical and experimental diabetes [12,13]. Similarly, 
the presence of neuroaxonal dystrophy in sympa-
thetic celiac/superior mesenteric ganglia (CG/SMG) 
has been observed in specimens from humans with 
diabetes and from rat and mouse models of type 1 
diabetes [10,11,14].
Microscopy studies at the light and ultrastructural 
level have revealed evidence for degenerative changes 
in autonomic nerves in experimental diabetes. With 
respect to the sympathetic supply to the small intes-
tine, dystrophic changes have been reported both 
within the CG/SMG, where the neuronal cell bodies are 
located, and in their axons supplying the ileum [11]. 
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Terminal tyrosine hydroxylase (TH)-containing nerve 
fibers within the target have swollen varicosities, a 
feature characteristic of a degenerative process [15]. 
Noradrenaline (NA) and its synthetic enzyme, TH, ac-
cumulate within the cell bodies of the CG/SMG pos-
sibly due to a defect in axonal transport, whereas both 
NA and TH levels are reduced in the target ileum [11,16]. 
A similar pattern has been observed for the intrinsic 
neurons containing vasoactive intestinal polypeptide 
(VIP) located in the myenteric plexus that innervate 
the smooth muscle of the ileum. VIP accumulates in 
the myenteric neuronal cell bodies, VIP-containing 
nerves fibers within the smooth musculature have 
swollen varicosities with ultrastructural evidence of 
degeneration and fail to release VIP on nerve stimu-
lation [15,17,18]. These features reflect the dying 
back type of distal axonopathy that is generally held 
to be the characteristic feature of diabetic autonomic 
neuropathy [11].
Whether neuronal cell death and loss of auto-
nomic neurons occur in diabetes remain a matter of 
controversy. The issue of neuronal cell death was 
raised when it was reported that both high glucose 
in vitro and STZ-diabetes in vivo caused apoptosis 
in sensory neurons located in the lumbar dorsal root 
ganglion (DRG), and it was suggested that this con-
tributes to the development of axonal degeneration 
[19]. Since this report, other studies of DRG in diabetes 
have found conflicting results [see reference 20 for 
review]. It has been proposed that diabetes may 
cause activation of caspases but that this may not 
progress fully down the apoptotic pathway to cause 
cell death [21]. In the sympathetic SMG, neuronal 
cell counts have not provided any evidence of neuronal 
loss in diabetes at a stage when degenerative changes 
in axons can readily be observed [22]. This implies 
that neuronal cell death is not a prerequisite for axon-
opathy to occur. However, apoptosis has been reported 
in the pelvic ganglion neurons containing neuronal 
nitric oxide synthase (nNOS) that supply erectile tissue 
in STZ-diabetic rats [13].
One important feature of autonomic neuropathy 
revealed by studies of experimental diabetes is that 
not all populations of autonomic nerves are affected 
in diabetes. Thus, neuroaxonal dystrophy and accu-
mulation of TH occur in the prevertebral sympathetic 
ganglion, the CG/SMG, but not in the paravertebral 
sympathetic superior cervical ganglion (SCG) from 
the same animals. Dystrophic changes occur in sym-
pathetic axons supplying the ileum, located in the 
mesentery, but not in the sympathetic axons supplying 
the mesenteric blood vessels [11]. Similarly, intrinsic 
myenteric neurons containing VIP undergo degener-
ative changes in diabetes whereas intrinsic myenteric 
neurons containing substance P or neuropeptide Y 
appear to be relatively unaffected [17,23]. In the pel-
vic ganglion, apoptosis has been reported to occur 
selectively in nNOS-containing parasympathetic neu-
rons in STZ-diabetic rats with sympathetic pelvic gan-
glion neurons containing TH being spared [13]. Why 
some autonomic nerves are more vulnerable in dia-
betes than others is an interesting question and an-
swering it could shed some light on the mechanisms 
underlying the development of autonomic neuropathy.
4. The pathogenesis of neuropathy
A number of theories have been proposed to ac-
count for the development of neuropathy in diabetes, 
including: diabetes-induced deficits in the blood supply 
to nerves; metabolic changes induced by hyperglyce-
mia; impaired nerve regeneration following a continu-
ous insult; Schwann cell abnormalities; and deficient 
neurotrophic support [4,20,24–27]. Since the Diabetes 
Control and Complications study [28] reported that 
the major factor that correlated with the presence of 
neuropathy in diabetic patients was the degree of glyce-
mic control, research has focused on the metabolic 
changes that can be induced by high levels of glucose. 
However, this does not preclude the involvement of 
the vascular supply and trophic support in neuropathy. 
Glucose-induced changes can not only affect axons 
directly but can also act by inducing changes either 
in the vascular system thus causing microangiopathy 
and reduced nerve blood flow or can affect Schwann 
cells thus impairing trophic support. Furthermore, 
neurotrophic factors may play a significant role in 
protecting the peripheral nervous system against 
the adverse consequences of glucose-induced meta-
bolic changes and in improving nerve regeneration 
in diabetes.
4.1. Oxidative stress induced by high 
glucose levels
Glucose enters neurons via facilitated concentration-
dependent transport. Therefore, hyperglycemia in di-
abetes results in increased intracellular concentrations 
of glucose that can lead to a number of metabolic 
changes, many of which cause oxidative stress. This 
has been reviewed extensively [see references 20, 
24, 29]. Oxidative stress occurs when there is a shift 
in the balance between the production of reactive 
oxygen species (ROS) and the antioxidant defence sys-
tems within a cell in favor of ROS production. Under 
normal conditions, the major site for formation of ROS 
is within mitochondria and this occurs as a by-product 
of oxidative phosphorylation. Neurons have a high 
level of metabolic activity and relatively high numbers 
of mitochondria. In common with other cells, they 
also have a variety of mechanisms to defend them-
selves against ROS. Within mitochondria, the two main 
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protective mechanisms are manganese superoxide 
dismutase (MnSOD) and glutathione peroxidase (GPx4). 
MnSOD converts superoxide anions to hydrogen per-
oxide while GPx4 converts hydrogen peroxide to water 
oxidizing glutathione in the process. Glutathione is a 
major intracellular antioxidant and has to be contin-
ually recycled from its oxidized form by the action of 
the enzyme glutathione reductase to maintain its anti-
oxidant capacity. In the cytoplasm, alternative forms 
of the antioxidant enzymes (Cu/ZnSOD and GPx1) are 
present and catalyze similar reactions. Additionally, 
catalase converts hydrogen peroxide to water. Vitamin 
C, vitamin E and taurine also all have antioxidant 
properties. Vitamin C acts in the aqueous environment 
of the cell whereas vitamin E acts within the hydro-
phobic environment of membranes. Taurine is not 
only an antioxidant but is also released from cells 
under conditions of osmotic stress to maintain the 
internal osmolarity of the cell.
Several metabolic changes have been proposed 
to occur as a consequence of high intracellular lev-
els of glucose leading to oxidative stress [20,24,29] 
(Fig. 1). The enzyme aldose reductase is activated to 
convert glucose to sorbitol during which process 
NADPH is oxidized to NADP+. Subsequently, sorbitol 
dehydrogenase converts sorbitol to fructose. Thus, 
increased aldose reductase activity has the potential 
to cause depletion of NADPH. One of the consequences 
of NADPH depletion is impaired recycling of the anti-
oxidant glutathione by glutathione reductase since 
this is also an NADPH-dependent enzyme. Increased 
intracellular glucose and fructose also cause osmotic 
stress stimulating the release and thus intracellular 
depletion of the antioxidant taurine. Glucose itself can 
undergo autoxidation, forming reactive species. Under 
normal conditions, glycation of macromolecules only 
occurs by an enzymatic process. However, at high con-
centrations, both glucose and fructose can glycate 
macromolecules via a nonenzymatic process. Following 
a series of chemical modifications, this results in the 
formation of advanced glycation endproducts (AGEs) 
that are not only highly reactive but can also act on 
the AGE receptor (RAGE), inducing oxidative stress.
Oxidative stress can lead to mitochondrial dys-
function, resulting in a vicious cycle in which increased 
mitochondrial production of ROS is induced following 
the production of ROS in the cytoplasm. However, a 
more direct pathway linking high glucose to increased 
ROS production by mitochondria has recently been 
proposed. High glucose levels can lead to high levels 
of NADH via the tricarboxylic acid cycle. Subsequently, 
excessive flux of NADH through the electron transport 
chain can lead to increased production of ROS by 
mitochondria. There is also preliminary evidence that 
diabetes can result in reduced expression of uncou-
pling protein-3. Uncoupling proteins dissipate the pro-
ton electrochemical gradient that is formed during 
respiration. Therefore, a reduction in uncoupling capac-
ity will impair the ability of mitochondria to dissipate 
the proton electrochemical gradient, favoring the pro-
duction of ROS [30]. It should be emphasized that the 
majority of the evidence for the metabolic changes 
described here has been obtained from in vitro studies 
of sensory neurons and it is generally assumed that 
similar mechanisms occur in vivo and also account 
for autonomic neuropathy.
4.2. Deficits in trophic factors
All the neurotrophins, nerve growth factor (NGF), 
brain-derived neurotrophic factor, neurotrophin-3 and 
neurotrophin-4, have been suggested to a greater or 
lesser extent to have a protective role in diabetes, 



















Fig. 1 — Schematic representation of the pathways that 
have been proposed to link the presence of hyperglyc-
emia in diabetes with the production of oxidative stress 
and the development of neuropathy. High intracellular 
levels of glucose can: undergo autoxidation; lead to the 
formation of advanced glycation endproducts (AGEs); 
and activate aldose reductase which, together with 
osmotic stress, can cause depletion of antioxidants. The 
presence of oxidative stress can lead to mitochondrial 
dysfunction resulting in a vicious cycle where the mito-
chondria produce more reactive oxygen species (ROS) 
in response. High glucose may also cause increased flux 
of NADH through the electron transport chain and may 
decrease expression of uncoupling proteins (UCPs), both 
of which favor increased mitochondrial ROS production 
leading to oxidative stress.
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has been implicated in the development of diabetic 
sensory neuropathy [see reference 25 for review]. 
NGF has received the greatest attention since it has 
the capacity to act on both small DRG neurons with 
nociceptive function and on autonomic sympathetic 
neurons. In vitro, NGF can protect against oxidative 
stress and induce the expression of antioxidant de-
fence enzymes [31,32]. NGF treatment of diabetic rats 
has been shown to prevent and/or reverse diabetes-
induced deficits in sensory neurons [33–35], although 
clinical trials have proved less successful [36]. In con-
trast, NGF treatment of rats had no beneficial effect 
on neuroaxonal dystrophy induced by diabetes in the 
sympathetic SMG neurons. Furthermore, treatment 
of control rats caused neuroaxonal dystrophy in the 
SMG [37]. Thus, it cannot be assumed that treatments 
for diabetic neuropathy will be equally successful for 
all subpopulations of peripheral neurons.
More recently, attention has been paid to the neuro-
trophic effects of the family of growth factors consisting 
of insulin-like growth factor 1 (IGF1), insulin and C pep-
tide. IGF1 resembles proinsulin, the precursor that is 
cleaved to produce insulin and C peptide. In type 1 
diabetes, there are reduced circulating levels of insulin, 
C peptide and IGF1 [25,38]. There is in vitro evidence 
that all three factors can increase neuronal survival 
and neurite outgrowth [39–41]. In addition, supplemen-
tation of diabetic rats with IGF1, insulin or C peptide 
has been shown to prevent the development of sen-
sory deficits in rats in vivo even when hyperglycemia 
is still present [38,42,43]. Furthermore, IGF1 reverses 
sympathetic neuroaxonal dystrophy in diabetic rats 
[44]. The significance of these findings is that it pro-
vides evidence that in type 1 diabetes, hyperglycemia 
may not be responsible for neuropathic changes on 
its own. The decrease in insulin and C peptide that 
accompanies hyperglycemia in type 1 diabetes may 
result in a loss of neurotrophic support that exacer-
bates the harmful effects of high glucose. Studies 
comparing animal models of type 1 and type 2 diabe-
tes have demonstrated more severe sensory neurop-
athy [38] and autonomic neuropathy [10,14] in type 1 
diabetes despite similar levels of hyperglycemia.
5. Differential responses of 
subpopulations of autonomic 
neurons to diabetes
5.1. Sympathetic neurons: in vivo studies
The question of differential vulnerability of subpopu-
lations of autonomic neurons to diabetes has received 
most attention with respect to the development of 
neuropathic changes in CG/SMG but not SCG neurons 
[see reference 11 for review]. In line with the obser-
vation of the glove-stocking distribution of peripheral 
neuropathy where the longest axons are affected to 
the greatest extent, one possible explanation consid-
ered was that the axons projecting from the CG/SMG 
are affected because they are longer than those pro-
jecting from the SCG. However, axons projecting from 
the sympathetic chain to supply mesenteric vessels 
are of equal length to those supplying the small in-
testine from the CG/SMG and they do not develop 
axonal dystrophy in diabetes. In addition, this could 
not explain the degenerative changes observed in in-
trinsic VIP-containing myenteric neurons where the 
axons only project short distances within the gastroin-
testinal tract. Differential influence of the target has 
also been considered since diabetes causes hypertro-
phy of the smooth musculature of the small intestine 
that is supplied by the CG/SMG. Together with deficient 
retrograde transport of NGF from the target, it was ini-
tially thought that loss of neurotrophic support for CG/
SMG neurons accounted for the selective development 
of neuroaxonal dystrophy. However, a later study re-
vealed that rather than reduced levels, NGF content 
was actually increased in the CG/SMG from diabetic 
rats whereas it was unchanged in the SCG [11].
This has led to the proposal that the intrinsic prop-
erties of sympathetic neurons may determine their 
susceptibility to diabetes. A comparison of gene ex-
pression in CG/SMG and SCG from rats has demon-
strated that there are marked differences in gene 
expression between the two ganglia under normal 
conditions. Furthermore, diabetes induced consider-
ably more changes in gene expression in CG/SMG than 
in SCG. Such changes in expression included genes 
involved in the structure and function of synapses and 
mitochondria and in oxidative stress [45]. The activi-
ties of the antioxidant enzymes glutathione peroxidase 
and superoxide dismutase have been shown to be 
considerably lower in CG/SMG than in SCG under nor-
mal conditions [46]. In addition, there is ultrastructural 
evidence that the blood–ganglion barrier is less effec-
tive in the CG/SMG [47]. Thus, sympathetic neurons 
from different ganglionic sources cannot be regarded 
as a homogeneous population that would necessarily 
respond in the same way to harmful stimuli.
5.2. Sympathetic and myenteric neurons: 
in vitro studies
Studies of isolated CG/SMG and SCG neurons in vitro
provide an approach in which a comparison can be 
made of their responses to high glucose or oxidative 
stress in the absence of hypoxia or the target changes 
that occur concurrently in diabetes in vivo. Primary 
cultures of neurons from adult rat CG/SMG and SCG 
have been investigated to avoid the confounding fac-
tor of developmental differences when using embry-
onic neurons. Neurons from both ganglia survived to 
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a similar extent in the absence of NGF. However, CG/
SMG neurons took longer to initiate neurite outgrowth 
than SCG neurons and exposure to high glucose in-
hibited this process [46]. Preliminary findings also 
indicated that NGF can protect SCG but not CG/SMG 
neurons against the harmful effects of high glucose 
(unpublished observations). Exposure of ganglion ex-
plants to menadione causes oxidative stress, as indi-
cated by the accumulation of the major product of lipid 
peroxidation, 4-hydroxynonenal. CG/SMG neurons were 
much more sensitive to oxidative stress than SCG neu-
rons. Significantly, low concentrations of menadione 
caused an accumulation of TH in CG/SMG but not in 
SCG neurons [48]. Thus, oxidative stress in vitro re-
sulted in the same differential accumulation of TH that 
occurs in diabetes in vivo. This provides evidence 
that the capacity of subpopulations of sympathetic 
neurons to withstand oxidative stress may be a major 
factor in determining their susceptibility to the devel-
opment of autonomic neuropathy in diabetes. It is in-
teresting to note that microtubules have been described 
as very susceptible to disruption by 4-hydroxynonenal, 
resulting in impaired axonal transport [49]. Therefore, 
this provides a mechanism whereby oxidative stress 
could result in axonopathy without necessarily caus-
ing apoptosis. Using cytochrome c oxidase activity as 
a marker of metabolic activity, preliminary evidence 
has been obtained demonstrating that CG/SMG neu-
rons display a higher range of metabolic activity than 
SCG neurons under normal conditions and that there 
is a positive correlation between accumulation of TH 
and high cytochrome c oxidase activity in CG/SMG 
neurons from diabetic rats (unpublished observations). 
Thus, it can be speculated that the level of meta-
bolic activity within a neuron may influence the de-
gree of oxidative stress that is induced under diabetic 
conditions.
In vitro studies have also been performed on whole-
mount preparations of the myenteric plexus from 
adult rat ileum. Exposure to high glucose levels in-
duces an accumulation of VIP and galanin in myenteric 
neuronal cell bodies, a response that is also observed 
in diabetes in vivo [50]. This indicates that hypertrophy 
of the muscle, which does not occur in vitro, is not 
involved in the process. Interestingly, high glucose 
levels did not induce the reduction in the proportion 
of myenteric neurons expressing nNOS that is observed 
in STZ-diabetic rats [51, unpublished observations]. 
In contrast, it has been reported that exposure of 
myenteric neurons to AGEs in vitro does result in the 
loss of nNOS expression [52]. A particular association 
between the presence of nNOS and the harmful effect 
of AGEs has been observed in pelvic ganglion neurons 
where nNOS-containing neurons undergo apoptosis 
in diabetes whereas TH-containing neurons do not 
[13]. Using a neuronal cell line, AGEs only initiated 
apoptosis in those cells in which the expression of 
nNOS had been induced [53]. This raises the possi-
bility that diabetes-induced changes in autonomic 
neurons may not always occur via the same mecha-
nism and that the particular neurotransmitter that an 
autonomic neuron expresses may also influence its 
susceptibility to the development of neuropathy in 
diabetes.
5.3. Differential responses to treatment
It is now evident that subpopulations of autonomic 
neurons not only have a differential susceptibility to 
the development of neuropathy in diabetes but that 
they also display a differential response to treatment. 
Experimental studies on the sensory nervous system 
have demonstrated that treatments with NGF [32], 
α-lipoic acid (an antioxidant) [54], aminoguanidine 
(an inhibitor of AGE formation) [55], and aldose re-
ductase inhibitors [56] can all prevent and/or reverse 
sensory deficits induced by diabetes. However, none of 
these agents are effective for treating diabetes-induced 
changes in CG/SMG neurons or their axons in the 
gastrointestinal tract [15,36,57,58]. To date, the only 
treatment that has been reported to reverse neuroax-
onal dystrophy in the CG/SMG has been IGF1 [44]. In 
addition, a study of α-lipoic acid revealed that whereas 
treatment with this antioxidant did prevent the loss 
of nNOS expression in erectile tissue and the loss of 
NA in the heart induced by diabetes, at the same dose, 
it failed to prevent the accumulation of VIP in mye-
nteric neurons or the loss of NA in the ileum that 
occurred in STZ-diabetic rats [58]. These findings have 
clinical implications in the search for effective treat-
ment of autonomic neuropathy in diabetic patients.
6. Summary
The significance of autonomic neuropathy in diabe-
tes has been underestimated. Clinical studies have 
been hampered by the difficulty in establishing non-
invasive techniques to evaluate autonomic function in 
specific target organs. Experimental studies have re-
vealed a complex pattern of change in diabetes in 
which different populations of autonomic neurons 
respond differently in diabetes with only some un-
dergoing degeneration. Characteristic neuropathic 
changes include accumulation of neurotransmitters 
within the neuronal cell body, loss of neurotransmitter 
in the nerve terminals with swelling of the varicosities 
and dystrophy. There is preliminary evidence that the 
intrinsic properties of autonomic neurons determine 
their response in diabetes. Increased metabolic activity 
and decreased antioxidant defence may predispose 
subpopulations of autonomic neurons to the devel-
opment of neuropathy. Clinical studies investigating 
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potential therapies for preventing or reversing dia-
betic neuropathy need to consider that damage to 
autonomic nerves, particularly those supplying the 
gastrointestinal tract, may be more difficult to treat.
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